{"page":{"totalFilteredElements":67},"studies":[{"active":true,"description":"A\nPhase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig\nor Pembrolizumab Monotherapy for the First-line Treatment of Patients with\nPD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)","eudractNumber":"2024-517780-24-00","id":10715,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06868277","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-30T08:10:04+01:00","shortTitle":"ARTEMIDE-Lung04","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Adjuvante Therapie mit Mitotane vs. Mitotane mit Cisplatin und Etoposid nach prim&#228;rer Resektion eines \nlokalisierten Nebennierenrindenkarzinoms mit hohem Rezidivrisiko (ADIUVO-2-Studie) - eine pragmatische, \nrandomisierte, minimalinterventionelle Phase III Studie mit Beobachtungsarm","eudractNumber":"2022-500013-32-01","id":10842,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":"NCT03583710","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-27T13:16:15+01:00","shortTitle":"Adjuvo-2 / AIO-ENC-0123/ass","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Allogene Stammzelltransplantation im Vergleich zur konventionellen \nTherapie als Salvage-Therapie f&#252;r Patienten mit rezidiviertem / \nprogredientem multiplen Myelom nach einer Erstlinientherapie\n(AlloRelapseMMStudy)","eudractNumber":"2021-001005-67","id":8119,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05675319","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-04-05T10:24:45+02:00","shortTitle":"AlloRelapseMMStudy - CTC201637","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Treatment protocol for mature aggressive B-cell-lymphoma and leukemia in children and adolescents<br />","eudractNumber":"2013-003253-21","id":2506,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":"NCT03206671","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2018-07-06T14:27:29+02:00","shortTitle":"B-NHL 2013","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide \n(CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and \nDexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): \nSUCCESSOR-2","eudractNumber":"2022-500861-29","id":10516,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05552976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-11T10:53:21+02:00","shortTitle":"BMS CA057-008 - SUCCESSOR-2","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator&#8217;s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge</div>","eudractNumber":"2024-517422-25","id":11018,"indications":[{"id":"pro","name":"Prostatakrebs"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-23T09:38:08+02:00","shortTitle":"BMS CA071-1000","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator&#8217;s Choice in Participants with Relapsed/Refractory Follicular Lymphoma</div><div>(GOLSEEK-4)</div>","eudractNumber":"2024-519152-82","id":11182,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06911502","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-24T13:25:31+02:00","shortTitle":"BMS CA0731003 GOLSEEK-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3, Randomized, Open-Label, Multicenter Study to 'Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Subjects with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma&#160;(QUINTESSENTIAL-2)","eudractNumber":"2022-501346-30-00","id":9854,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06615479","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-01T09:47:06+02:00","shortTitle":"BMS CA088-1007","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"<div>A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus</div><div>Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with</div><div>Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung</div><div>Cancer with KRAS G12C Mutation (KRYSTAL-4)</div>","eudractNumber":"2024-515698-85-00","id":11377,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"KRAS","id":"mt_7"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS-G12C","id":"mt_250"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06875310","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-30T08:29:20+02:00","shortTitle":"BMS CA239-0004 (KRYSTAL-4)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Liverage<sup>TM</sup> - A randomised, double-blind, placebo-controlled, multicentre, phase III trial evaluating long-term efficacy and safety off survodutide weekly injections in adult particpants with non-cirrhotic, non-alcoholic steatohepatitis - metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis","eudractNumber":"2024-513739-25-00","id":11353,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT06632444","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-30T14:22:17+02:00","shortTitle":"Boehringer Ingelheim 1404-0044","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}